Biochemical and functional characterization of lysyl oxidase like 2 (LOXL2) inhibitors Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome Source: Eur Respir J, 57 (5) 2001416; 10.1183/13993003.01416-2020 Year: 2021
LATE-BREAKING ABSTRACT: Inhibition of the ubiquitin-E3-ligase FBXW7 enhances steroid efficacy: New concept for treating steroid insensitivity Source: International Congress 2015 – Asthma mechanisms and management Year: 2015
Altered protein homeostasis in pulmonary fibrosis indicates a role for proteasomal activator 200 Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014
Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Role of lysyl oxidases in pathogenesis of pulmonary emphysema Source: International Congress 2017 – Insight into the pathogenesis of emphysema and pneumonia Year: 2017
Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019
Dysregulated elastin remodelling in bronchopulmonary dysplasia: a role for lysyl oxidases? Source: Eur Respir J 2007; 30: Suppl. 51, 377s Year: 2007
Dipeptidyl peptidase I (DPPI) cleaves surfactant protein D (SP-D): A mechanism for immune compromise in the lung Source: International Congress 2016 – Molecular immunology of the lung Year: 2016
LSC Abstract – Inhibition of oxygen sensing HIF prolyl hydroxylases in humans presents a novel therapeutic target for the fibrotic lung Source: International Congress 2015 – Treatment of IPF Year: 2015
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Treatment of bronchiolitis obliterans syndrome: where are we now? Source: Annual Congress 2011 - Novelties in lung transplantation Year: 2011
Oral presentation: Potential of ACE2 as a therapeutic target for pulmonary hypertension Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010
Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via co-application of a neutral endopeptidase 24.11 inhibitor Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015
Human airway trypsin-like protease: Friend or foe in idiopathic pulmonary fibrosis? Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
DRESS to Impress: A Case of Eosinophilic Bronchiectasis with Systemic Sequelae Source: Virtual Congress 2021 – CCC Paediatric respiratory diseases Year: 2021
Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis Source: Eur Respir J 2013; 42: 404-413 Year: 2013
Anti-inflammatory action of Gibberellin in lung epithelial cells is mediated by modification of NF-κB related kinase expression Source: International Congress 2014 – Mechanistic studies of the airway epithelium Year: 2014
Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014